Hiroshi Hashimoto

Hiroshi Hashimoto

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Yoshikane YamauchiYoshikane Yamauchi
Yoshikane Yamauchi
JNJun Nakajima
Jun Nakajima
MMMingyon Mun
Mingyon Mun
Yasushi ShintaniYasushi Shintani
Yasushi Shintani
HKHiroaki Kuroda
Hiroaki Kuroda
OJon behalf of the Metastatic Lung Tumor Study Group of Japan
on behalf of the Metastatic Lung Tumor Study Group of Japan
To clarify the clinical impact and to identify prognostic predictors of surgical intervention for pulmonary metastasis from esophageal cancer, a registry database analysis was performed. From January 2000 to March 2020, patients who underwent resection of pulmonary metastases from primary esophageal cancer at 18 institutions were registered in a database developed by the Metastatic Lung Tumor Study Group of Japan. An amount of 109 cases were reviewed and examined for the prognostic factors for pulmonary metastasectomy of metastases from esophageal cancer. As a result, five-year overall survival after pulmonary metastasectomy was 34.4% and five-year disease-free survival was 22.1%. The multivariate analysis for overall survival revealed that initial recurrence site, maximum tumor size, and duration from primary tumor treatment to lung surgery were selected as the significant prognostic factors (p = 0.043, p = 0.048, and p = 0.037, respectively). In addition, from the results of the multivariate analysis for disease free survival, number of lung metastases, initial recurrence site, duration from primary tumor treatment to lung surgery, and preoperative chemotherapy for lung metastasis were selected as the significant prognostic factors (p = 0.037, p = 0.008, p = 0.010, and p = 0.020, respectively). In conclusion, eligible patients with pulmonary metastasis from esophageal cancer selected based on the identified prognostic predictors would be good candidates for pulmonary metastasectomy.

29 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Yoshikane YamauchiYoshikane Yamauchi
Yoshikane Yamauchi
MSMasaaki Sato
Masaaki Sato
TITakekazu Iwata
Takekazu Iwata
MEMakoto Endo
Makoto Endo
NINorihiko Ikeda
Norihiko Ikeda
YSYukinori Sakao
Yukinori Sakao
Background/objectives: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies. In this study, we aimed to assess the prognostic outcomes of excising pulmonary metastases from urothelial carcinoma. Methods: In this study, we utilized data from the Metastatic Lung Tumor Study Group of Japan database, a multi-institutional prospective database of pulmonary metastasectomies. We examined the data of patients who had undergone pulmonary metastasectomy for urothelial carcinoma between 1985 and 2021. Exclusion criteria included insufficient clinical information and follow-up of <3 months. Results: The study cohort comprised 100 patients (63 bladder cancer, 37 renal pelvic and ureteral cancer), with a median follow-up of 34 months. There were 70 male and 30 female patients of average age 66.5 ± 10.4 years at lung metastasectomy. The median interval from treatment of the primary lesion to metastasectomy was 19 months and the maximum tumor diameter was 21 ± 15 mm. Three- and five-year overall survival rates were 69% and 59%, respectively. Three- and five-year disease-free survival rates were 56% and 46%, respectively. Multivariate analysis identified larger tumor diameter (hazard ratio: 1.62, 95% confidence interval: 1.21–2.17) and distant metastases at the time of treatment of the primary cancer (hazard ratio: 4.23; 95% confidence interval: 1.54–11.6) as significant adverse prognostic factors for overall survival. Conclusions: To our knowledge, this is the largest published case series of pulmonary resection for metastatic urothelial carcinoma, providing benchmark data for the assessment of long-term outcomes of this rare entity.

2 April 2022 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
HHHiroshi Hashimoto
Hiroshi Hashimoto
KKKazuyuki Komori
Kazuyuki Komori
KKKoji Kameda
Koji Kameda
STShinichi Taguchi
Shinichi Taguchi
YOYuichi Ozeki
Yuichi Ozeki
Background: Anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement. However, its treatment after failure of initial ALK–TKI therapy remains controversial. Case presentation: A 47-year-old woman with a hemosputum was diagnosed with adenocarcinoma of the left lung (cT2bN3M0, stage IIIB). Gene mutation analysis indicated positive ALK translocation. Alectinib was selected as the first-line treatment. Although the treatment effect was determined as a partial response, the main tumor regrew. Alectinib was discontinued, and salvage surgery was performed without causing morbidity. The pathological diagnosis was pleomorphic carcinoma without lymph node metastasis (yp-T2bN0). After surgery, lorlatinib was administered as the second-line treatment for 8 months until the patient could not tolerate continuation. Computed tomography scan revealed no lung cancer recurrence 14 months after discontinuation. Conclusions: Our experience with this case suggests that salvage surgery after alectinib treatment followed by lorlatinib therapy may be effective for initially unresectable ALK-positive NSCLC.

1 January 2021 in International Journal of Case Reports and Images
Verified
Journal Article
Open access
KKKazuyuki Komori
Kazuyuki Komori
HHHiroshi Hashimoto
Hiroshi Hashimoto
KYKotaro Yoshikawa
Kotaro Yoshikawa
KKKoji Kameda
Koji Kameda
STShinichi Taguchi
Shinichi Taguchi
YOYuichi Ozeki
Yuichi Ozeki

1 January 2019 in International Journal of Case Reports and Images
Verified
Journal Article
Open access
HHHiroshi Hashimoto
Hiroshi Hashimoto
YOYuichi Ozeki
Yuichi Ozeki
KKKoji Kameda
Koji Kameda
HSHideyuki Shimazaki
Hideyuki Shimazaki
STShinichi Taguchi
Shinichi Taguchi
Introduction: Primary thymic adenocarcinoma is a notably rare neoplasm. Here, we described a case of non-papillary thymic adenocarcinoma that was comparable to adenocarcinoma not otherwise specified (NOS) according to the recent WHO classification. Case Report: A 69-year-old woman presented to our hospital with an anterior mediastinal tumor. Thymothymectomy was performed. Histological examination revealed dense proliferation of irregular tubular and partially solid atypical cells with fibrous stroma. Based on pathological and immunohistochemical findings, and the absence of primary tumors in other sites, a diagnosis of primary thymic adenocarcinoma NOS was established. Recently, enteric-type adenocarcinoma was detected in a subset of adenocarcinoma NOS, but the current case was not of this type. The patient was alive without any sign of recurrence 30 months postoperatively. Conclusion: Our case report suggests that some adenocarcinomas NOS are not enteric and that this finding should be further evaluated.

25 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HTHikaru Takahashi
Hikaru Takahashi
Yoshikane YamauchiYoshikane Yamauchi
Yoshikane Yamauchi
TNTomoki Nishida
Tomoki Nishida
MYMasahiro Yanagiya
Masahiro Yanagiya
HHHiroshi Hashimoto
Hiroshi Hashimoto
YSYukinori Sakao
Yukinori Sakao
Background: Predicting long-term outcomes after pulmonary metastasectomy for colorectal cancer remains challenging because existing prognostic methods lack precision. We developed and validated a prognostic scoring system derived from a major international meta-analysis to improve risk stratification and to evaluate the benefit of adjuvant chemotherapy across risk groups. Methods: Using a Japanese registry of 819 patients who underwent lung resection between 2010 and 2019, we constructed a 0–13-point score based on eight variables including tumor size, number, biological markers, and intrathoracic lymph node status, which may require intraoperative or pathological confirmation. Granular data on chemotherapy regimens, timing, and duration were unavailable. Patients were classified as low, intermediate, or high risk. The primary analysis used inverse probability of treatment weighting to adjust for baseline imbalances; however, only 819 of 1657 patients (49.4%) had complete prognostic data, introducing potential selection bias. Results: The score separated patients into three groups with distinct five-year survival rates: 81.1% (low), 67.8% (intermediate), and 59.1% (high). In high-risk patients, chemotherapy was associated with improved overall survival but did not delay recurrence. In low-risk patients, chemotherapy correlated with reduced recurrence-free survival, a finding that persisted after adjustment. Conclusions: This validated scoring system aids individualized surgical decision making by identifying patients unlikely to benefit from routine postoperative chemotherapy. Observed survival advantages in high-risk patients may reflect selection of fitter individuals rather than direct treatment effects, underscoring the need to address selection bias in future trials.